In a breakthrough for India’s pharmaceutical sector, firms including Hetero, Cipla, Annora, and Natco have won Chinese government bids to supply generic drugs like Dapagliflozin and Olaparib, marking a significant entry into China’s tightly controlled healthcare market
PHARMEXCIL DG Ravi Uday Bhaskar said India’s pharmaceuticals export during April 2022 till March 2023 was US$ 25.4 billion, registering a growth rate of nearly three percent.
Hyderabad: Indian pharma industry is going through a lot of transformation and achieving scale. While export opportunities keep increasing, there is equal attention on strengthening the drug pipeline driven by research investments. Speaking at the CEO Conclave at BioAsia on Friday, Ajay Piramal, chairman, Piramal Group said, the company is increasing its investments onto more […]
Hyderabad: Indian pharma needs to move from low-risk research and innovation to high-risk research and innovation. And that’s where the country is lagging. Investing in high-risk innovation is very capital intensive and the return on that investment is both uncertain and long-term. To aid innovation, there needs to be adequate risk capital and a different […]
